Oral administration is considered the most favorable route of administration than injection because of convenience and compliance by patients, resulting in improved treatment efficacy, but it is challenging for biologic drugs like insulin. In our lab, we designed a novel multi-stage nanoparticle delivery system designed to overcome all of the barriers of the gastrointestinal tract and provide efficient oral delivery of insulin. In which the nanoparticles will protect the biologic from the adverse environment in the gastrointestinal tract, get actively transported across the intestinal barrier, and rapidly release their payload to effectively deliver and maximize the efficacy of the biologic. This technology is expected to have a significant impact on diseases that are currently limited to injection-based therapies, notably diabetes.
- Pridgen EM, Alexis F, Kuo TT, Levy-Nissenbaum E, Karnik R, Blumberg RS, Langer R, and Farokhzad OC, “Transepithelial transport of fc-targeted nanoparticles by the neonatal fc receptor for oral delivery” Science Translational Medicine, 5, 213ra167 (2013). PMCID: PMC4023672. Full Text
- Wu J, Kamaly N, Shi J, Zhao L, Xiao Z, Hollett G, John R, Ray S, Xu X, Zhang X, Kantoff PW and Farokhzad OC, “Development of multinuclear polymeric nanoparticles as robust protein nanocarriers” Angewandte Chemie International Edition 53 (34), 8975-8979 (2014). PMCID:PMC4143165. Full Text
- Lim JM, Swami A, Gilson LM, Chopra S, Choi S, Wu J, Langer RS, Karnik R, and Farokhzad OC, “High-throughput synthesis of nanoparticles in a versatile coaxial turbulent jet mixer” ACS Nano 8, 6056-6065 (2014). PMCID:PMC407240. Full Text
- Choi W, Kamaly N, Riol-Blanco L, Lee IH, Wu J, Swami A, Vilos C, Yameen B, Yu M, Shi JJ, Tabas I, von Andrian UH, Jon S, and Farokhzad OC, “A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins” Nano Letters 14 (11), 6449-6455 (2014). PMCID: PMC4245989. Full Text
- Zhu X, Xu Y, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J., Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment, Proc Natl Acad Sci U S A. (2015) Jun 23;112(25):7779-84. Full Text